866-997-4948(US-Canada Toll Free)

Type 2 Diabetes - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Diabetes

No. of Pages : 417 Pages


Type 2 Diabetes Pipeline Review, H2 2012

Global Markets Directs, \'Type 2 Diabetes Pipeline Review, H2 2012\', provides an overview of the Type 2 Diabetes therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 2 Diabetes. \'Type 2 Diabetes Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Type 2 Diabetes.
  • A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Type 2 Diabetes pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Type 2 Diabetes therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Type 2 Diabetes Therapeutic Products under Development, Key Players in Type 2 Diabetes Therapeutics, Type 2 Diabetes Pipeline Overview, Type 2 Diabetes Pipeline, Type 2 Diabetes Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Type 2 Diabetes Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Type 2 Diabetes 17
Type 2 Diabetes Therapeutics under Development by Companies 19
Type 2 Diabetes Therapeutics under Investigation by Universities/Institutes 31
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
Type 2 Diabetes Therapeutics Products under Development by Companies 38
Type 2 Diabetes Therapeutics Products under Investigation by Universities/Institutes 59
Companies Involved in Type 2 Diabetes Therapeutics Development 61
Bristol-Myers Squibb Company 61
Johnson & Johnson 62
Boehringer Ingelheim GmbH 63
F. Hoffmann-La Roche Ltd. 64
Abbott Laboratories 65
Shionogi & Co., Ltd. 66
NsGene A/S 67
Medinox, Inc. 68
Amgen Inc. 69
Sanofi-Aventis 70
AstraZeneca PLC 71
Eli Lilly and Company 72
GlaxoSmithKline plc 73
MedImmune LLC 74
Isis Pharmaceuticals, Inc. 75
Gilead Sciences, Inc. 76
Merck & Co., Inc. 77
Dainippon Sumitomo Pharma Co., Ltd. 78
Taisho Pharmaceutical Co., Ltd. 79
Euroscreen S.A. 80
Novo Nordisk A/S 81
Generex Biotechnology Corporation 82
Takeda Pharmaceutical Company Limited 83
Plexxikon Inc. 84
BioLineRx, Ltd. 85
Ipsen S.A. 86
Piramal Healthcare Limited 87
Senexis Limited 88
Nycomed International Management GmbH 89
Neurocrine Biosciences, Inc. 90
Novartis AG 91
Amylin Pharmaceuticals, Inc. 92
Astellas Pharma Inc. 93
Biocon Limited 94
Chong Kun Dang Pharmaceutical 95
Panacea Biotec Limited 144
Summit Corporation plc 145
OctoPlus N.V. 146
DiaMedica Inc. 147
Debiopharm Group 148
Advinus Therapeutics Pvt. Ltd. 149
Betagenon AB 150
Chipscreen Biosciences Ltd 151
ActogeniX NV 152
Camurus AB 153
Sirtris Pharmaceuticals, Inc. 154
Phosphagenics Limited 155
Domain Therapeutics 156
7TM Pharma A/S 157
Metabolex, Inc 158
Spherix Incorporated 159
Curatis Pharma GmbH 160
Arisaph Pharmaceuticals, Inc. 161
AngioChem Inc. 162
Allozyne, Inc. 163
Metabolic Solutions Development Co. 164
Catabasis Pharmaceuticals, Inc. 165
PhaseBio Pharmaceuticals, Inc. 166
Five Prime Therapeutics, Inc. 167
Melior Discovery, Inc. 168
DiaKine Therapeutics, Inc. 169
Intarcia Therapeutics, Inc. 170
Theracos, Inc. 171
Versartis, Inc. 172
InteKrin Therapeutics, Inc. 173
NOXXON Pharma AG 174
Avaxia Biologics, Inc. 175
Intercept Pharmaceuticals, Inc. 176
Omeros Corporation 177
Transtech Pharma, Inc. 178
BRIDGE BIORESEARCH PLC 179
Targacept, Inc. 180
Sirona Biochem Corp 199
ReceptorBio, Inc. 200
XBiotech USA, Inc. 201
Connexios Life Sciences Pvt. Ltd. 202
PharmaIN Corporation 203
Stempeutics Research Private Limited 204
EMS S.A. 205
Type 2 Diabetes Therapeutics Assessment 206
Assessment by Monotherapy Products 206
Assessment by Combination Products 207
Assessment by Route of Administration 208
Assessment by Molecule Type 211
Drug Profiles 214
Dapagliflozin - Drug Profile 214
Onglyza - Drug Profile 216
Tenelia - Drug Profile 218
Dulaglutide - Drug Profile 220
tofogliflozin - Drug Profile 222
ASP-1941 - Drug Profile 223
TAK-875 - Drug Profile 225
SYR-472 - Drug Profile 227
Lyxumia - Drug Profile 228
Ryzodeg - Drug Profile 230
Nesina - Drug Profile 232
IN-105 - Drug Profile 234
Chiglitazar - Drug Profile 235
Empagliflozin - Drug Profile 236
SK-0403 - Drug Profile 238
Ranexa - Drug Profile 240
Albiglutide - Drug Profile 242
exenatide - Drug Profile 245
Afrezza - Drug Profile 247
Naturlose - Drug Profile 249
TS-071 - Drug Profile 251
UNI-rE-4 - Drug Profile 252
lobeglitazone - Drug Profile 254
Tresiba - Drug Profile 255
TA-7284 - Drug Profile 257
TA-7284 - Drug Profile 259
Levemir + Liraglutide + Metformin - Drug Profile 261
Sitagliptin - Drug Profile 263
Alogliptin + Metformin - Drug Profile 265
Dapagliflozin + Metformin XR - Drug Profile 266
LY 2605541 - Drug Profile 268
Gemigliptin - Drug Profile 270
IDegLira - Drug Profile 271
Linjeta - Drug Profile 273
Cholecalciferol - Drug Profile 275
Metformin - Drug Profile 276
Metformin + Rosiglitazone - Drug Profile 278
Albiglutide + Metformin - Drug Profile 279
Albiglutide + Metformin + Glimepiride - Drug Profile 281
Janumet - Drug Profile 283
Novorapid + Amaryl - Drug Profile 284
Albiglutide + Insulin Glargine - Drug Profile 286
MP-513 + Thiazolidinedione - Drug Profile 288
MP-513 + Sulfonylurea - Drug Profile 289
Hydroxychloroquine - Drug Profile 290
ASP-1941 + Metformin - Drug Profile 291
Lixisenatide + Lantus - Drug Profile 293
BI 10773 + Metformin - Drug Profile 295
ASP-1941 + Pioglitazone - Drug Profile 297
Acarmet - Drug Profile 298
New Formulation Insulin Glargine - Drug Profile 299
LY 2963016 - Drug Profile 301
Liovel - Drug Profile 302
Liovel - Drug Profile 304
Surepost + Pioglitazone - Drug Profile 306
Surepost + Metformin - Drug Profile 307
Metgluco - Drug Profile 308
Sitagliptin + Acarbose - Drug Profile 309
BI 10773 + Metformin + Sulfonylurea - Drug Profile 311
Dulaglutide + Insulin Lispro - Drug Profile 313
Acarbose - Drug Profile 315
ASP-1941 + Nateglinide - Drug Profile 316
Januvia + Metformin + Glimepiride - Drug Profile 317
CJ-30001 + CJ-30002 - Drug Profile 319
LY2963016 + OAMs - Drug Profile 320
ASP-1941 + Alpha-Glucosidase Inhibitor - Drug Profile 322
Insulin + Metformin - Drug Profile 323
ASP-1941 + DPP-4 Inhibitor - Drug Profile 325
Glufast + Biguanide - Drug Profile 326
Glufast + DPP-4 Inhibitor - Drug Profile 327
Victoza + Januvia + Metformin - Drug Profile 328
Kombiglyze XR - Drug Profile 330
BI 10773 + Pioglitazone - Drug Profile 332
BI 10773 + BI 1356 - Drug Profile 334
CKD-501 + Metformin - Drug Profile 335
MK-0431E - Drug Profile 337
BMS-477118 + BMS-512148 + Metformin - Drug Profile 338
Surepost + DPP4 Inhibitors - Drug Profile 340
Type 2 Diabetes Therapeutics Drug Profile Updates 341
Type 2 Diabetes Therapeutics Discontinued Products 376
Type 2 Diabetes Therapeutics - Dormant Products 385
Type 2 Diabetes Product Development Milestones 403
Featured News & Press Releases 403

Appendix 411
Methodology 411
Coverage 411
Secondary Research 411
Primary Research 411
Expert Panel Validation 411
Contact Us 412
Disclaimer 412

List of Table


Number of Products Under Development for Type 2 Diabetes, H2 2012 22
Products under Development for Type 2 Diabetes Comparative Analysis, H2 2012 23
Number of Products under Development by Companies, H2 2012 25
Number of Products under Development by Companies, H2 2012 (Contd..1) 26
Number of Products under Development by Companies, H2 2012 (Contd..2) 27
Number of Products under Development by Companies, H2 2012 (Contd..3) 28
Number of Products under Development by Companies, H2 2012 (Contd..4) 29
Number of Products under Development by Companies, H2 2012 (Contd..5) 30
Number of Products under Development by Companies, H2 2012 (Contd..6) 31
Number of Products under Development by Companies, H2 2012 (Contd..7) 32
Number of Products under Development by Companies, H2 2012 (Contd..8) 33
Number of Products under Development by Companies, H2 2012 (Contd..9) 34
Number of Products under Development by Companies, H2 2012 (Contd..10) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Comparative Analysis by Late Stage Development, H2 2012 39
Comparative Analysis by Mid Clinical Stage Development, H2 2012 40
Comparative Analysis by Early Clinical Stage Development, H2 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 42
Products under Development by Companies, H2 2012 43
Products under Development by Companies, H2 2012 (Contd..1) 44
Products under Development by Companies, H2 2012 (Contd..2) 45
Products under Development by Companies, H2 2012 (Contd..3) 46
Products under Development by Companies, H2 2012 (Contd..4) 47
Products under Development by Companies, H2 2012 (Contd..5) 48
Products under Development by Companies, H2 2012 (Contd..6) 49
Products under Development by Companies, H2 2012 (Contd..7) 50
Products under Development by Companies, H2 2012 (Contd..8) 51
Products under Development by Companies, H2 2012 (Contd..9) 52
Products under Development by Companies, H2 2012 (Contd..10) 53
Products under Development by Companies, H2 2012 (Contd..11) 54
Products under Development by Companies, H2 2012 (Contd..12) 55
Products under Development by Companies, H2 2012 (Contd..13) 56
Products under Development by Companies, H2 2012 (Contd..14) 57
Products under Development by Companies, H2 2012 (Contd..15) 58
Products under Development by Companies, H2 2012 (Contd..16) 59
Products under Development by Companies, H2 2012 (Contd..17) 60
Products under Development by Companies, H2 2012 (Contd..18) 61
Products under Development by Companies, H2 2012 (Contd..19) 62
Products under Development by Companies, H2 2012 (Contd..20) 63
Products under Investigation by Universities/Institutes, H2 2012 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 65
Bristol-Myers Squibb Company, H2 2012 66
Johnson & Johnson, H2 2012 67
Boehringer Ingelheim GmbH, H2 2012 68
F. Hoffmann-La Roche Ltd., H2 2012 69
Abbott Laboratories, H2 2012 70
Shionogi & Co., Ltd., H2 2012 71
NsGene A/S, H2 2012 72
Medinox, Inc., H2 2012 73
Amgen Inc., H2 2012 74
Sanofi-Aventis, H2 2012 75
AstraZeneca PLC, H2 2012 76
Eli Lilly and Company, H2 2012 77
GlaxoSmithKline plc, H2 2012 78
MedImmune LLC, H2 2012 79
Isis Pharmaceuticals, Inc., H2 2012 80
Gilead Sciences, Inc., H2 2012 81
Merck & Co., Inc., H2 2012 82
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 83
Taisho Pharmaceutical Co., Ltd., H2 2012 84
Euroscreen S.A., H2 2012 85
Novo Nordisk A/S, H2 2012 86
Generex Biotechnology Corporation, H2 2012 87
Takeda Pharmaceutical Company Limited, H2 2012 88
Plexxikon Inc., H2 2012 89
BioLineRx, Ltd., H2 2012 90
Ipsen S.A., H2 2012 91
Piramal Healthcare Limited, H2 2012 92
Senexis Limited, H2 2012 93
Nycomed International Management GmbH, H2 2012 94
Neurocrine Biosciences, Inc., H2 2012 95
Novartis AG, H2 2012 96
Amylin Pharmaceuticals, Inc., H2 2012 97
Astellas Pharma Inc., H2 2012 98
Biocon Limited, H2 2012 99
Chong Kun Dang Pharmaceutical, H2 2012 100
Chugai Pharmaceutical Co. Ltd, H2 2012 101
Dong-A Pharmaceutical Co., Ltd., H2 2012 102
Forest Laboratories, Inc., H2 2012 103
Glenmark Pharmaceuticals Ltd., H2 2012 104
Japan Tobacco Inc., H2 2012 105
Kissei Pharmaceutical Co., Ltd., H2 2012 106
Mitsubishi Tanabe Pharma Corporation, H2 2012 107
MDRNA, Inc., H2 2012 108
Pfizer Inc., H2 2012 109
Ranbaxy Laboratories Limited, H2 2012 110
Sigma-Tau S.p.A., H2 2012 111
VIVUS, Inc., H2 2012 112
Zydus Cadila Healthcare Limited, H2 2012 113
Hadasit Medical Research Services & Development Ltd, H2 2012 114
TransPharma Medical Ltd., H2 2012 115
Biodel Inc., H2 2012 116
MannKind Corporation, H2 2012 117
Halozyme Therapeutics, H2 2012 118
Addex Pharmaceuticals, H2 2012 119
Evotec Aktiengesellschaft, H2 2012 120
GW Pharmaceuticals plc, H2 2012 121
Hollis-Eden Pharmaceuticals, Inc., H2 2012 122
Enzo Biochem, Inc., H2 2012 123
Genfit, H2 2012 124
Ligand Pharmaceuticals Incorporated, H2 2012 125
Lotus Pharmaceuticals, Inc., H2 2012 126
Lupin Limited, H2 2012 127
Mesoblast Ltd, H2 2012 128
PROLOR Biotech, Inc., H2 2012 129
Oramed Pharmaceuticals, Inc., H2 2012 130
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 131
ConjuChem Biotechnologies Inc., H2 2012 132
Lexicon Pharmaceuticals, Inc., H2 2012 133
Arena Pharmaceuticals, Inc., H2 2012 134
BTG International Ltd, H2 2012 135
Flamel Technologies S.A., H2 2012 136
ProteoTech, Inc., H2 2012 137
SANWA KAGAKU KENKYUSHO CO.,LTD., H2 2012 138
Yuhan Corporation, H2 2012 139
Emisphere Technologies, Inc., H2 2012 140
XOMA Ltd., H2 2012 141
IPCA Laboratories Limited, H2 2012 142
Lipoxen PLC, H2 2012 143
LG Life Sciences, Ltd, H2 2012 144
Transition Therapeutics Inc., H2 2012 145
DARA BioSciences, Inc., H2 2012 146
SemBiosys Genetics Inc., H2 2012 147
Uni-Bio Science Group Ltd., H2 2012 148
Panacea Biotec Limited, H2 2012 149
Summit Corporation plc, H2 2012 150
OctoPlus N.V., H2 2012 151
DiaMedica Inc., H2 2012 152
Debiopharm Group, H2 2012 153
Advinus Therapeutics Pvt. Ltd., H2 2012 154
Betagenon AB, H2 2012 155
Chipscreen Biosciences Ltd, H2 2012 156
ActogeniX NV, H2 2012 157
Camurus AB, H2 2012 158
Sirtris Pharmaceuticals, Inc., H2 2012 159
Phosphagenics Limited, H2 2012 160
Domain Therapeutics, H2 2012 161
7TM Pharma A/S, H2 2012 162
Metabolex, Inc, H2 2012 163
Spherix Incorporated, H2 2012 164
Curatis Pharma GmbH, H2 2012 165
Arisaph Pharmaceuticals, Inc., H2 2012 166
AngioChem Inc., H2 2012 167
Allozyne, Inc., H2 2012 168
Metabolic Solutions Development Co., H2 2012 169
Catabasis Pharmaceuticals, Inc., H2 2012 170
PhaseBio Pharmaceuticals, Inc., H2 2012 171
Five Prime Therapeutics, Inc., H2 2012 172
Melior Discovery, Inc., H2 2012 173
DiaKine Therapeutics, Inc., H2 2012 174
Intarcia Therapeutics, Inc., H2 2012 175
Theracos, Inc., H2 2012 176
Versartis, Inc., H2 2012 177
InteKrin Therapeutics, Inc., H2 2012 178
NOXXON Pharma AG, H2 2012 179
Avaxia Biologics, Inc., H2 2012 180
Intercept Pharmaceuticals, Inc., H2 2012 181
Omeros Corporation, H2 2012 182
Transtech Pharma, Inc., H2 2012 183
BRIDGE BIORESEARCH PLC, H2 2012 184
Targacept, Inc., H2 2012 185
N-Gene Research Laboratories, Inc., H2 2012 186
Obio Pharmaceutical Holdings Limited., H2 2012 187
ChemoCentryx, Inc., H2 2012 188
VIA Pharmaceuticals, Inc., H2 2012 189
KYORIN Pharmaceutical Co., Ltd., H2 2012 190
Novocell, Inc., H2 2012 191
Verva Pharmaceuticals Limited, H2 2012 192
Napo Pharmaceuticals, Inc., H2 2012 193
DiAthegen, LLC, H2 2012 194
NasVax Ltd., H2 2012 195
Stelic Institute & Co., H2 2012 196
Adamed Sp. z o.o., H2 2012 197
Pharnext SAS, H2 2012 198
The Alize Pharma Group, H2 2012 199
Ardelyx, Inc., H2 2012 200
Heptares Therapeutics Ltd., H2 2012 201
Ascendis Pharma A/S, H2 2012 202
MicroDose Therapeutx, Inc., H2 2012 203
Sirona Biochem Corp, H2 2012 204
ReceptorBio, Inc., H2 2012 205
XBiotech USA, Inc., H2 2012 206
Connexios Life Sciences Pvt. Ltd., H2 2012 207
PharmaIN Corporation, H2 2012 208
Stempeutics Research Private Limited, H2 2012 209
EMS S.A., H2 2012 210
Assessment by Monotherapy Products, H2 2012 211
Assessment by Combination Products, H2 2012 212
Assessment by Stage and Route of Administration, H2 2012 215
Assessment by Stage and Molecule Type, H2 2012 218
Type 2 Diabetes Therapeutics Drug Profile Updates 346
Type 2 Diabetes Therapeutics Discontinued Products 381
Type 2 Diabetes Therapeutics Discontinued Products (Contd..1) 382
Type 2 Diabetes Therapeutics Discontinued Products (Contd..2) 383
Type 2 Diabetes Therapeutics Discontinued Products (Contd..3) 384
Type 2 Diabetes Therapeutics Discontinued Products (Contd..4) 385
Type 2 Diabetes Therapeutics Discontinued Products (Contd..5) 386
Type 2 Diabetes Therapeutics Discontinued Products (Contd..6) 387
Type 2 Diabetes Therapeutics Discontinued Products (Contd..7) 388
Type 2 Diabetes Therapeutics Discontinued Products (Contd..8) 389
Type 2 Diabetes Therapeutics Dormant Products 390
Type 2 Diabetes Therapeutics Dormant Products (Contd..1) 391
Type 2 Diabetes Therapeutics Dormant Products (Contd..2) 392
Type 2 Diabetes Therapeutics Dormant Products (Contd..3) 393
Type 2 Diabetes Therapeutics Dormant Products (Contd..4) 394
Type 2 Diabetes Therapeutics Dormant Products (Contd..5) 395
Type 2 Diabetes Therapeutics Dormant Products (Contd..6) 396
Type 2 Diabetes Therapeutics Dormant Products (Contd..7) 397
Type 2 Diabetes Therapeutics Dormant Products (Contd..8) 398
Type 2 Diabetes Therapeutics Dormant Products (Contd..9) 399
Type 2 Diabetes Therapeutics Dormant Products (Contd..10) 400
Type 2 Diabetes Therapeutics Dormant Products (Contd..11) 401
Type 2 Diabetes Therapeutics Dormant Products (Contd..12) 402
Type 2 Diabetes Therapeutics Dormant Products (Contd..13) 403
Type 2 Diabetes Therapeutics Dormant Products (Contd..14) 404
Type 2 Diabetes Therapeutics Dormant Products (Contd..15) 405
Type 2 Diabetes Therapeutics Dormant Products (Contd..16) 406
Type 2 Diabetes Therapeutics Dormant Products (Contd..17) 407

List of Chart


Number of Products under Development for Type 2 Diabetes, H2 2012 22
Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 211
Assessment by Combination Products, H2 2012 212
Assessment by Route of Administration, H2 2012 213
Assessment by Stage and Route of Administration, H2 2012 214
Assessment by Molecule Type, H2 2012 216
Assessment by Stage and Molecule Type, H2 2012 217

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *